section name header

Information

Synonym/Acronym

cytoplasmic antineutrophil cytoplasmic antibody (c-ANCA), perinuclear antineutrophil cytoplasmic antibody (p-ANCA).

Rationale

To assist in diagnosis and monitoring of therapeutic interventions for glomerulonephritis, vasculitis, and granulomatosis with polyangiitis (GPA) (formerly Wegener granulomatosis [WG]).

Patient Preparation

There are no food, fluid, activity, or medication restrictions unless by medical direction.

Normal Findings

(Method: Indirect immunofluorescence for ANCA, both types) Negative; Multiplex Flow Immunoassay for Proteinase 3 antibodies.

Antineutrophil Cytoplasmic Antibodies
P-ANCA or C-ANCANegative
Proteinase 3 Antibodies
Less than 0.4 UNegative
0.4-0.9 UEquivocal
Greater than or equal to 1 UPositive

Critical Findings and Potential Interventions

N/A

Overview

(Study type: Blood collected in a red-top tube; related body system: Circulatory, digestive, immune, respiratory, urinary systems.)

Antineutrophil cytoplasmic autoantibodies (ANCA) have long been associated with vasculitis (inflammation of the blood vessels) and glomerulonephritis. Although progress has been made in understanding this association, the exact etiology of ANCA-associated vasculitis is unclear. Whatever the actual mechanism, there is a connection between ANCAs, activated neutrophils, the formation of neutrophil extracellular traps (NETs), and instigation of NETosis, a type of neutrophil cell death. The immune function of NETs is to entrap pathogens and other “foreign” targets. Neutrophil activation is involved in other diseases and is triggered by exposure to things other than ANCAs. NET research is an active area of study with demonstrated connections to the development of other conditions such as cancer, coagulation disorders, diabetes, rheumatoid arthritis, and systemic lupus erythematosus.

The most thoroughly studied theory suggests that ANCAs may activate neutrophils and also target cell surface proteins (myeoloperoxidase [MPO] and proteinase 3 [PR3]). Activated neutrophils produce NETs, fiberlike structures that are pushed out into circulation from activated neutrophils. The NETs become stuck to the walls of capillaries and other small vessels, a process that subsequently initiates the process of NETosis. When NETosis occurs, inflammatory fragments of nuclear material (e.g., DNA) and enzymes are released. The dying neutrophils break apart and release cytoplasmic components that include the granular inclusion proteins MPO and PR3. The proteins, which are associated with the neutrophils’ cell surfaces and cytoplasmic granules, become circulating targets, and the autoimmune response from ANCAs deepens. Other than the ANCA and specific PR3 blood studies, tissue biopsy is the definitive test with presence of granuloma being the positive finding.

ANCAs react with enzymes in the cytoplasmic granules of neutrophils and can be identified by their cellular staining characteristics when present. The most common types of cytoplasmic granules include PR3, MPO, cathepsin G, elastase, and lactoferrin. PR3-ANCA and MPO-ANCA are most associated with ANCA-associated vasculitides.

c-ANCA (cytoplasmic) is most often associated with the PR3 proteinase in neutrophils and monocytes and is found in the sera of patients with GPA, an autoimmune vasculitis that primarily affects the kidneys and lungs. Autoantibodies to PR3 develop in GPA. Antibodies to PR3-ANCA produce a characteristic pattern of granular cytoplasmic fluorescence called the cytoplasmic ANCA pattern. GPA includes granulomatous inflammation of the upper and lower respiratory tract and vasculitis.

p-ANCA (perinuclear) is most often associated with myeloperoxidase MPO and produces a perinuclear cytoplasmic staining pattern. Antibodies to MPO-ANCA occur predominately in patients with microscopic polyangiitis (MPA); p-ANCA is also present in the sera of patients with pauci-immune necrotizing glomerulonephritis.

Indications

Interfering Factors

N/A

Potential Medical Diagnosis: Clinical Significance of Results

Increased In

  • c-ANCA/PR3 antibodies
    • GPA and its variants (granulomatosis with polyangiitis is most often associated with PR3 antibodies)
  • p-ANCA/MPO antibodies are most often associated with microscopic polyangiitis, although c-ANCA and atypical ANCAs (typically against elastase or lactoferrin) may also be associated
    • Alveolar hemorrhage, diffuse
    • Angiitis and polyangiitis
    • Autoimmune liver disease
    • Capillaritis
    • Churg-Strauss syndrome
    • Crescentic glomerulonephritis
    • Crohn disease
    • Felty syndrome
    • Pauci-immune necrotizing glomerulonephritis
    • Leukocytoclastic vasculitis
    • Microscopic polyangiitis
    • Primary sclerosing cholangitis
    • Rheumatoid arthritis
    • Ulcerative colitis
    • Vasculitis (ANCA-associated small vessel vasculitis)

Decreased In

N/A

Nursing Implications

Before the Study: Planning and Implementation

Teaching the Patient What to Expect

  • Discuss how this test can assist in identifying the cause of inflammatory activity in the small arterial blood vessels of the kidneys, lungs, and nasopharynx.
  • Explain that a blood sample is needed for the test.

Potential Nursing Actions

  • Monitor for symptoms that are commonly seen with a diagnosis of GPA.
  • Assess for symptoms related to altered kidney function (related to presence of hematuria or RBC casts)
  • Assess for symptoms related to altered respiratory function (related to cough, dyspnea, and/or abnormal chest x-ray showing nodules or infiltrates)
  • Assess for symptoms related to altered skin (cutaneous) integrity (related to skin lesions)
  • Assess for symptoms related to musculoskeletal changes (related to painful or arthritic joints)
  • Assess for ear, nose, and throat alterations (related to chronic sinusitis, chronic otitis media, hearing loss, oral ulcers, and/or abnormal nasal discharge)

After the Study: Implementation & Evaluation Potential Nursing Actions

Avoiding Complications

  • Ensure adequate oxygenation with a saturation greater than 92%, as adequate oxygenation will support body function.

Treatment Considerations

  • The main goal for treatment of GPA is reducing inflammation within the blood vessels in order to prevent further damage to associated sites (kidneys, lungs, nasopharynx) and to decrease risk for other complications (eyes, ears, skin, joints), and cytotoxic drugs (related to immune system suppression).
  • Discuss how a combination of immune suppressant treatment options may be used to treat GPA; corticosteroids (initially administered in high doses to reduce inflammation and then gradually tapered down), antibiotics (related to infections that arise in immunosuppressed patients), and cytotoxic drugs (related to immune system suppression).
  • Interventions/actions related to the disease process include the following: Assess for infection by monitoring and trending laboratory studies: BUN, Cr, WBC count, Hgb, Hct, electrolytes, and urine including complementary diagnostic studies: CT, IVP, KUB, and MRI. Monitor and trend temperature, which can be an early indicator of change of status. Assess respiratory status establishing baseline: rate, rhythm, depth, and work of breathing. Administer ordered oxygen and use pulse oximetry to assess and maintain adequate oxygenation. Elevate the head of the bed to facilitate breathing. Monitor and trend arterial blood gas results. Assess for cyanosis as indicators of worsening respiratory status. Administer ordered medications (antibiotics, cytotoxic drugs, corticosteriods). Increase oral fluid intake as appropriate to support hydration with administration of ordered parenteral fluids to support nutrition.

Clinical Judgement

  • Consider the emotional impact of a compromised respiratory status and what can be done to alleviate anxiety and maximize breathing.

Follow-Up Evaluation and Desired Outcomes

  • Understands that GPA can lead to fatal lung or kidney failure without therapeutic treatment. However, a full recovery may be possible with early diagnosis and treatment.
  • Acknowledges the importance of vigilant adherence when taking medications designed to suppress the immune system, and corticosteroids to treat GPA.